Andrew H. Limper

Andrew H. Limper, M.D., is a Professor of Medicine and Biochemistry at Mayo Clinic, holding joint appointments in the Department of Internal Medicine and the Department of Biochemistry and Molecular Biology. He leads the Thoracic Diseases Research Unit, focusing on lung infections (e.g., fungal pneumonias) and interstitial lung diseases. His research integrates molecular immunology, clinical trials, and AI-driven diagnostics to improve outcomes for immunocompromised patients and those with pulmonary fibrosis. Key roles include Director of the Thoracic Diseases Research Unit (2012–2024), Chair of Pulmonary and Critical Care (2004–2012), and Robert D. and Patricia E. Kern Associate Dean for Practice Transformation (2017–2021).

• Education: MD from University of Illinois at Peoria; BS in Chemistry-Physiology from University of Illinois at Urbana-Champaign.

Research interests span fungal pathogenesis, lung fibrosis mechanisms, and translational medicine. His team employs large datasets, radiological imaging, and machine learning to advance early diagnosis and treatment. Notable achievements include identifying novel therapies for fungal infections and improving diagnostic accuracy for pulmonary fibrosis. He has secured grants from NIH and other bodies, including projects on EphA2 receptor pathways in PCP and macrophage activation in Pneumocystis pneumonia.

Awards: Walter and Leonore Annenberg Professorship in Pulmonary Medicine (2006–present).

Grants & Projects: Active research includes NIH-funded projects on fungal immunity and lung disease mechanisms. Prior leadership roles in multi-institutional studies like SPIROMICS and the Women’s Health Initiative Regional Center underscore his collaborative approach.

Labs/Teams: Thoracic Diseases Research Unit at Mayo Clinic, integrating clinician-scientists to study asthma, COPD, lung cancer, and vasculitis alongside his primary focus areas.